Clinical trial · Observational
AMH Predicts Postchemotherapy Menopause in Premenopausal Breast Cancer Patients
A Prospective, Observational Clinical Study of AMH Predicting Postchemotherapy Menopause in Premenopausal Breast Cancer Patients Who do Not Use OFS
NCT06313476CI-TRIAL-00075055unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To determine the accuracy of AMH postchemotherapy in predicting permanent menopause after chemotherapy in breast cancer patients who did not use OFS before menopause
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Patients
- description
- Premenopausal patients with early breast cancer who received chemotherapy (neoadjuvant chemotherapy or adjuvant chemotherapy) and did not use OFS ovarian suppression at the Breast Cancer Center of Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Primary outcomes (1)
- measure
- Anti-Mullerian Hormone
- timeFrame
- Before chemotherapy, within a week after last chemotherapy, 1,3,6,12,18,24 months after chemotherapy
- description
- Blood Test
Secondary outcomes (3)
- measure
- Estradiol
- timeFrame
- Before chemotherapy, within a week after last chemotherapy, 1,3,6,12,18,24 months after chemotherapy
- description
- Blood Test
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 40 Years
- Maximum age
- 59 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age over 40(include 40 years old), or before 60, female 2. Primary invasive breast cancer diagnosed by histopathology, except of occult breast cancer, inflammatory breast cancer and Paget's disease 3. Operable patients with no distant metastases at diagnosis (stage T1-T3, any N, M0) 4. The patient was at premenopausal status when first diagnosed (had menstruation in the last 12 months or hormone levels not reached menopause when diagnosed, E2 \> 30ng/L, FSH≤30U/L) 5. The patient has used chemotherapy (neoadjuvant chemotherapy or adjuvant chemotherapy) after diagnosis Exclusion Criteria: 1. Age before 40, or over 60(include 60 years old) 2. Patient who accepted bilateral ovariectomy or ovarian radiotherapy 3. Patient who used gonadotropin-releasing hormone agonist ( GnRHa) 4. Stage IV (metastatic) breast cancer 5. The patient was at postmenopausal status when first diagnosed (no menstruation in the past 12 months or hormone levels reached menopause when diagnosed, E2≤30ng/L, FSH \> 30U/L) 6. The patient has not used chemotherapy (neoadjuvant or adjuvant chemotherapy) since diagnosis 7. The investigator determines that the patient has any other condition that make her unfit to participate in the study
References
Publications (0)
Data not yet available
No reference posted for this study.